Accordingly, Gly-MCA, a new high-affinity intestinal FXR antagonist, was designed that is structurally and functionally similar to T-β-MCA and demonstrated stability in the gut and resistance to hydrolysis into β-MCA by BSH and improvement of HFD-induced obesity and insulin resistance (11). The gene discussed is NR1H4; the disease is obesity disorder.